RxDoctor Payments Data

Brian Hunter, MD

Ophthalmology · Tucson, AZNPI 1528264793

Payments from drug & device makers

$3,564in general payments, 2019–2025

Across 117 payments — averaging $30.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Surgical Vision, Inc.$759
  • Rxsight Inc$560
  • Glaukos Corporation$448
  • Alcon$385
  • AbbVie$246
  • Carl Zeiss Meditec, Inc.$232
  • plus $933 from 13 others

What the payments were for

  • Speaking & faculty fees$511%
  • Food & beverage$3,47297%
  • Education$411%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,564 in reported general payments places this provider in the 65th percentile of 310 ophthalmology providers in Arizona.

See all ophthalmology providers in Arizona

Medicare billing

Part B allowed, 2024
$476,393
Medicare patients
1,270
Services billed
3,175

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XdemvyLotilaner42$78,498
RestasisCyclosporine54$75,213
XiidraLifitegrast50$75,112
LumiganBimatoprost61$32,498
Cyclosporine43$23,512
VyzultaLatanoprostene Bunod37$11,719
Tobradex StTobramycin/Dexamethasone15$5,953
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol31$4,973
ProlensaBromfenac Sodium11$3,894
Prednisolone Acetate112$3,384
Latanoprost212$1,973
Brimonidine Tartrate41$1,700
Timolol Maleate80$815
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat39$506
Gatifloxacin14$501

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$246$107,711115 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$72$86,83187 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$72$78,49842 claims
Eyevance Pharmaceuticals LLCTobradex St$115$5,95315 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$71$3,89411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 310 ophthalmology providers in Arizona.

Other ophthalmology in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →